Cardiac tissue engineering and regeneration using cell-based therapy

Stem Cells and Cloning: Advances and Applications

Volumn 8, Issue , 2015, Pages 81-101

  Alrefai, Mohammad T ^a,b   Murali, Divya ^c   Paul, Arghya ^c   Ridwan, Khalid M ^a   Connell, John M ^a   Shum Tim, Dominique ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c University of Kansas   (United States)

Author keywords

Cardiac surgery; Cardiomyocytes; Cell sheet and tissue engineering; Heart; Heart failure; Myocardial ischemia; Organoids; Scaffolds; Stem cells

Indexed keywords

ALGINIC ACID; BIOMIMETIC MATERIAL; CHITOSAN; COLLAGEN; FIBRIN; GLYCERYL TRINITRATE; HYALURONIC ACID; MACROGOL; MATRIGEL; POLY(N ISOPROPYLACRYLAMIDE); POLYGLACTIN; POLYMACON;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADIPOSE DERIVED STEM CELL; ADULT STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIAC STEM CELL; CELL DIFFERENTIATION; CONGESTIVE CARDIOMYOPATHY; CORD BLOOD STEM CELL TRANSPLANTATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY OCCLUSION; CORONARY STENT; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; FETUS HEART; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; MYOBLAST; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PLURIPOTENT STEM CELL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE SCAFFOLD;

EID: 84930947528     PISSN: None     EISSN: 11786957     Source Type: Journal    
DOI: 10.2147/SCCAA.S54204     Document Type: Review

References (211)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095–2128.
2. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Eng J Med. 2001;344(23): 1750–1757.
3. Reddi AH, Huggins CB. Influence of geometry of transplanted tooth and bone on transformation of fibroblasts. Proc Soc Exp Biol Med. 1973; 143(3):634–637.
4. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. Nat Med. 2008;14(2):213–221.
5. Paschos NK, Brown WE, Eswaramoorthy R, Hu JC, Athanasiou KA. Advances in tissue engineering through stem cell-based co-culture. J Tissue Eng Regen Med. 2014 . Epub February 3.
6. Scorsin M, Hagege AA, Marotte F, et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium? Circula­tion. 1997;96(9 Suppl):188-193.
7. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Med. 1996;62(3):654–660.
8. Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002;91(6):501–508.
9. Lee AS, Tang C, Cao F, et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle. 2009;8(16):2608–2612.
10. Gluckman E. Ten years of cord blood transplantation: from bench to bedside. Br J Haematol. 2009;147(2):192–199.
11. Henning RJ, Burgos JD, Vasko M, et al. Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size. Cell Transplant. 2007;16(9):907–917.
12. Wang L, Deng J, Tian W, et al. Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts. Am J Physiol Heart Circ Physiol. 2009;297(3): H1020–H1031.
13. Valina C, Pinkernell K, Song YH, et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J. 2007;28(21):2667–2677.
14. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4(8):929–933.
15. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first random­ized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189–1200.
16. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112(12):1748–1755.
17. Orlic D, Kajstura J, Chimenti C, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701–705.
18. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance func­tion of infarcted rat hearts. Nat Biotechnol. 2007;25(9):1015–1024.
19. Beltrami AP, Barlucchi L, Torella D. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–776.
20. Messina E, De Angelis L, Frati G. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9): 911–921.
21. Oh H, Bradfute SB, Gallardo TD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313–12318.
22. Beltrami AP et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–776
23. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and trans-differentiations. Annu Rev Cell Dev Biol. 2001;17:387–403.
24. Tang XL, Rokosh G, Sanganalmath SK, et al. Intracoronary adminis­tration of cardiac progenitor cells alleviates left ventricular dysfunc­tion in rats with a 30-day-old infarction. Circulation. 2010;121(2):293–305.
25. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007;104(35):14068–14073.
26. Linke A, Müller P, Nurzynska D, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A. 2005;102(25):8966–8971.
27. Urbanek K, Cesselli D, Rota M, et al. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci U S A. 2006;103(24):9226–9231.
28. Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–1857.
29. Pérez-Pomares JM, de la Pompa JL. Signaling during epicardium and coronary vessel development. Circ Res. 2011;109(12):1429–1442.
30. Tian X, Hu T, Zhang H, et al. Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res. 2013;23(9):1075–1090.
31. Cossette S, Misra R. The identification of different endothelial cell populations within the mouse proepicardium. Dev Dyn. 2011;240(10): 2344–2353.
32. Tomanek RJ. Formation of the coronary vasculature: a brief review. Cardiovasc Res. 1996;31 Spec No:E46–E51.
33. Kattman SJ, Witty AD, Gagliardi M, et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 2011;8(2): 228–240.
34. Ye L, Zimmermann WH, Garry DJ, Zhang J. Patching the heart: cardiac repair from within and outside. Circ Res. 2013;113(7):922–932.
35. Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A, Yau TM. Survival and function of bioengineered cardiac grafts. Circulation. 1999;100(19 Suppl):63-69.
36. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391): 1145–1147.
37. Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453(7194):524–528.
38. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo car­diomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012;10(1):16–28.
39. Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry CE. Endogenous Wnt/beta-catenin signaling is required for cardiac differen­tiation in human embryonic stem cells. PloS One. 2010;5(6):e11134.
40. Ueno S, Weidinger G, Osugi T, et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci U S A. 2007;104(23):9685–9690.
41. Naito AT, Shiojima I, Akazawa H, et al. Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogen­esis and hematopoiesis. Proc Natl Acad Sci U S A. 2006;103(52): 19812–19817.
42. Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentia­tion from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27): E1848–E1857.
43. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012; 485(7400):593–598.
44. Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485(7400): 599–604.
45. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res. 2012;111(1):50–55.
46. Addis RC, Epstein JA. Induced regeneration – the progress and prom­ise of direct reprogramming for heart repair. Nat Med. 2013;19(7):829–836.
47. Kim C, Majdi M, Xia P, et al. Non-cardiomyocytes influence the elec­trophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev. 2010;19(6): 783–795.
48. Pasumarthi KB, Field LJ. Cardiomyocyte enrichment in differentiat­ing ES cell cultures: strategies and applications. Methods Mol Biol. 2002;185:157–168.
49. Anderson D, Self T, Mellor IR, Goh G, Hill SJ, Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther. 2007;15(11):2027–2036.
50. Uosaki H, Fukushima H, Takeuchi A, et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PloS One. 2011; 6(8):e23657.
51. Dubois NC, Craft AM, Sharma P, et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol. 2011;29(11):1011–1018.
52. Tohyama S, Hattori F, Sano M, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2013;12(1):127–137.
53. Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Murry CE. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J Mol Cell Cardiol. 2010;49(6):941–949.
54. Lloyd-Jones D, Adams RJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.
55. Rumyantsev PP. Growth and Hyperplasia of Cardiac Muscle Cells. 1st ed. London: Taylor and Francis; 1991:1–371.
56. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 1998;83(1):15–26.
57. Anversa P, Kajstura J. Ventricular myocytes are not terminally differenti­ated in the adult mammalian heart. Circ Res. 1998;83(1):1–14.
58. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98–102.
59. Michler RE. Stem cell therapy for heart failure. Cardiol Rev. 2014;22(3): 105–116.
60. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesen­chymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10(3):244–258.
61. Dauwe DF, Janssens SP. Stem cell therapy for the treatment of myocar­dial infarction. Curr Pharm Des. 2011;17(30):3328–3340.
62. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132(3):628–632.
63. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012;125(1):100–112.
64. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167(10):989–997.
65. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone mar­row cell homing into the infarcted human myocardium. Circulation. 2005;111(17):2198–2202.
66. Ellison GM, Vicinanza C, Smith AJ, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell. 2013;154(4):827–842.
67. Ellison GM, Torella D, Dellegrottaglie S, et al. Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol. 2011;58(9):977–986.
68. Waring CD, Vicinanza C, Papalamprou A, et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur Heart J. 2014;35(39): 2722–2731.
69. Nadal-Ginard B, Ellison GM, Torella D. The cardiac stem cell com­partment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult. Stem Cell Res. 2014;13(3 Pt B):615–630.
70. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treat­ment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59(5):539–540.
71. Strauer BE, Brehm M, Zeus T, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplan­tation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol. 2005;46(9):1651–1658.
72. Stamm C, Kleine HD, Choi YH, et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg. 2007;133(3):717–725.
73. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115(25): 3165–3172.
74. Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013;165(6):854–861.
75. van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009;301(19):1997–2004.
76. Zhao Q, Sun Y, Xia L, Chen A, Wang Z. Randomized study of mono­nuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Med. 2008;86(6):1833–1840.
77. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI).Circulation. 2002;106(24):3009–3017.
78. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell trans­fer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-ele­vation infarct regeneration) trial. Circulation. 2006; 113(10):1287–1294.
79. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-mar­row cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141–148.
80. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199–1209.
81. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mono­nuclear cell therapy. J Am Coll Cardiol. 2010;55(13):1385–1394.
82. Schächinger V, Erbs S, Elsässer A, et al; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23): 2775–2783.
83. Tendera M, Wojakowski W, Ruzyłło W, et al; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30(11):1313–1321.
84. Gyöngyösi M, Lang I, Dettke M, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med. 2009;6(1):70–81.
85. Sürder D, Manka R, Lo Cicero V, et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation. 2013; 127(19):1968–1979.
86. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–2119.
87. Traverse JH, Henry TD, Vaughan DE, et al; Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4):412–420.
88. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379(9819):895–904.
89. Perin EC, Sanz-Ruiz R, Sánchez PL, et al. Adipose-derived regenera­tive cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J. 2014;168(1):88–95.
90. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autolo­gous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107(18):2294–2302.
91. Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capac­ity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyo­pathy. Circulation. 2004;110(11 Suppl 1):213-218.
92. Assmus B, Fischer-Rasokat U, Honold J, et al; TOPCARE-CHD Registry. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart fail­ure: results of the TOPCARE-CHD Registry. Circ Res. 2007;100(8): 1234–1241.
93. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–2379.
94. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12(7): 721–729.
95. Fischer-Rasokat U, Assmus B, Seeger FH, et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progeni­tor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and func­tional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail. 2009;2(5):417–423.
96. Patnaik SS, Wang B, Weed B, Wertheim JA, Liao J. Decellularized scaffolds: concepts, methodologies, and applications in cardiac tissue engineering and whole-organ regeneration. In: Liu Q, Wang H, editors. Tissue Regeneration: Where Nanostructure Meets Biology. Singapore: World Scientific; 2014:77–124.
97. Zimmermann W, Melnychenko I, Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials. 2004;25(9): 1639–1647.
98. Bursac N, Papadaki M, Cohen RJ, et al. Cardiac muscle tissue engi­neering: toward an in vitro model for electrophysiological studies. Am J Physiol. 1999;277(2 Pt 2):H433–H444.
99. Müller-Ehmsen J, Whittaker P, Kloner RA, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol. 2002;34(2):107–116.
100. Reinecke H, Murry CE. Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology. J Mol Cell Cardiol. 2002;34(3):251–253.
101. Yang YL, Motte S, Kaufman LJ. Pore size variable type I collagen gels and their interaction with glioma cells. Biomaterials. 2010;31(21): 5678–5688.
102. Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004;10(3–4):403–409.
103. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117(11):1388–1396.
104. Giraud MN, Ayuni E, Cook S, Siepe M, Carrel TP, Tevaearai HT. Hydrogel-based engineered skeletal muscle grafts normalize heart function early after myocardial infarction. Artif Organs. 2008;32(9): 692–700.
105. Lu WN, Lü SH, Wang HB, et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A. 2009;15(6):1437–1447.
106. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracel­lular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005;23(1):47–55.
107. Dobner S, Bezuidenhout D, Govender P, Zilla P, Davies N. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J Card Fail. 2009;15(7):629–636.
108. Klouda L, Mikos AG. Thermoresponsive hydrogels in biomedical applications. Eur J Pharm Biopharm. 2008;68(1):34–45.
109. Nelson DM, Ma Z, Fujimoto KL, Hashizume R, Wagner WR. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomater. 2011;7(1):1–15.
110. Leor J, Amsalem Y, Cohen S. Cells, scaffolds, and molecules for myo­cardial tissue engineering. Pharmacol Ther. 2005;105(2):151–163.
111. Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol. 2006;48(5):907–913.
112. Davis ME, Hsieh PC, Grodzinsky AJ, Lee RT. Custom design of the cardiac microenvironment with biomaterials. Circ Res. 2005;97(1): 8–15.
113. Huang NF, Yu J, Sievers R, Li S, Lee RJ. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng. 2005;11(11–12):1860–1866.
114. Reffelmann T, Kloner RA. Cellular cardiomyoplasty – cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? Cardiovasc Res. 2003;58(2):358–368.
115. Kellar RS, Shepherd BR, Larson DF, Naughton GK, Williams SK. Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng. 2005;11(11–12): 1678–1687.
116. Robinson KA, Li J, Mathison M, et al. Extracellular matrix scaffold for cardiac repair. Circulation. 2005;112(9 Suppl):I135–I143.
117. Zimmermann WH, Melnychenko I, Wasmeier G, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. 2006;12(4):452–458.
118. Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol. 2009;54(11): 1014–1023.
119. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expres­sion is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res. 2002;55(2):329–340.
120. Yoshida M, Oh H. Stem cell engineering for cardiac tissue regenera­tion. Cardiology. 2010;115(3):191–193.
121. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials. 2009;30(29):5409–5416.
122. Zimmermann WH, Eschenhagen T. Cardiac tissue engineering for replacement therapy. Heart Fail Rev. 2003;8(3):259–269.
123. Kutschka I, Chen IY, Kofidis T, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation. 2006;114(1 Suppl): I167–I173.
124. Koch MA, Vrij EJ, Engel E, Planell JA, Lacroix D. Perfusion cell seeding on large porous PLA/calcium phosphate composite scaffolds in a perfusion bioreactor system under varying perfusion parameters. J Biomed Mater Res A. 2010;95(4):1011–1018.
125. Dvir T, Timko BP, Brigham MD, et al. Nanowired three-dimensional cardiac patches. Nat Nanotechnol. 2011;6(11):720–725.
126. Bilodeau K, Mantovani D. Bioreactors for tissue engineering: focus on mechanical constraints. A comparative review. Tissue Eng. 2006;12(8):2367–2383.
127. Radisic M, Marsano A, Maidhof R, Wang Y, Vunjak-Novakovic G. Cardiac tissue engineering using perfusion bioreactor systems. Nat Protoc. 2008;3(4):719–738.
128. Tandon N, Marsano A, Cannizzaro C, Voldman J, Vunjak-Novakovic G. Design of electrical stimulation bioreactors for cardiac tissue engineering. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:3594–3597.
129. Radisic M, Park H, Shing H, et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci U S A. 2004;101(52):18129–18134.
130. Davis ME, Motion JP, Narmoneva DA, et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation. 2005;111(4):442–450.
131. Khait L, Birla RK. Cell-based cardiac pumps and tissue-engineered ventricles. Regen Med. 2007;2(4):391–406.
132. Lee EJ, Kim do E, Azeloglu EU, Costa KD. Engineered cardiac organoid chambers: toward a functional biological model ventricle. Tissue Eng Part A. 2008;14(2):215–225.
133. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng. 2011;13:27–53.
134. Singelyn JM, Christman KL. Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J Cardiovasc Transl Res. 2010;3(5):478–486.
135. Schenke-Layland K, Vasilevski O, Opitz F, et al. Impact of decel­lularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves. J Struct Biol. 2003;143(3):201–208.
136. Moroni F, Mirabella T. Decellularized matrices for cardiovascular tissue engineering. Am J Stem Cells. 2014;3(1):1–20.
137. Breuer CK, Mettler BA, Anthony T, Sales VL, Schoen FJ, Mayer JE. Application of tissue-engineering principles toward the development of a semilunar heart valve substitute. Tissue Eng. 2004;10(11–12): 1725–1736.
138. Iop L, Bonetti A, Naso F, et al. Decellularized allogeneic heart valves demonstrate self-regeneration potential after a long-term preclinical evaluation. PloS One. 2014;9(6):e99593.
139. Oberwallner B, Brodarac A, Choi YH, et al. Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium. J Biomed Mater Res A. 2014;102(9):3263–3272.
140. Freytes DO, Stoner RM, Badylak SF. Uniaxial and biaxial properties of terminally sterilized porcine urinary bladder matrix scaffolds. J Biomed Mater Res B Appl Biomater. 2008;84(2):408–414.
141. Wang B, Borazjani A, Tahai M, et al. Fabrication of cardiac patch with decellularized porcine myocardial scaffold and bone marrow mononuclear cells. J Biomed Mater Res A. 2010;94(4):1100–1110.
142. Wainwright JM, Czajka CA, Patel UB, et al. Preparation of cardiac extracellular matrix from an intact porcine heart. Tissue Eng Part C Methods. 2010;16(3):525–532.
143. Ozawa T, Mickle DA, Weisel RD, Koyama N, Ozawa S, Li RK. Optimal biomaterial for creation of autologous cardiac grafts. Circulation. 2002;106(12 Suppl 1):I176–I182.
144. Weber B, Emmert MY, Schoenauer R, Brokopp C, Baumgartner L, Hoerstrup SP. Tissue engineering on matrix: future of autologous tissue replacement. Semin Immunopathol. 2011;33(3):307–315.
145. Zou Y, Zhang Y. Mechanical evaluation of decellularized porcine thoracic aorta. J Surg Res. 2012;175(2):359–368.
146. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med. 2011;17(8):424–432.
147. Chang Y, Chen SC, Wei HJ, Wu TJ, Liang HC, Lai PH, et al. Tissue regeneration observed in a porous acellular bovine pericardium used to repair a myocardial defect in the right ventricle of a rat model. J Thorac Cardiovasc Surg. 2005;130(3):705–711.
148. Badylak SF, Kochupura PV, Cohen IS, Doronin SV, Saltman AE, Gilbert TW, et al. The use of extracellular matrix as an inductive scaffold for the partial replacement of functional myocardium. Cell Transplant. 2006;15:S29–S40.
149. Ota T, Gilbert TW, Badylak SF, Schwartzman D, Zenati MA. Elec­tromechanical characterization of a tissue-engineered myocardial patch derived from extracellular matrix. J Thorac Cardiovasc Surg. 2007;133(4):979–985.
150. Robinson KA, Li J, Mathison M, Redkar A, Cui J, Chronos NA, et al. Extracellular matrix scaffold for cardiac repair. Circulation. 2005;112(9S):I135–I143.
151. Fu RH, Wang YC, Liu SP, et al. Decellularization and recellularization technologies in tissue engineering. Cell Transplant. 2014;23(4–5): 621–630.
152. Azhim A, Narita Y, Muramatsu K, Morimoto Y, Tanaka M. Decellularization of living tissue using microwave chemical process for tissue-engineered scaffold applications. In: Lim CT, Goh JC, editors. International Con­ference on Biomedical Engineering Proceedings. Vol 31, 6th World Congress of Biomechanics (WCB 2010): August 1–6, 2010, Singapore: In Conjunction with 14th International Conference on Biomedical Engi­neering (ICBME) and 5th Asia Pacific Conference on Biomechanics (APBiomech). Berlin and Heidelberg: Springer; 2010:934–937.
153. Akhyari P, Aubin H, Gwanmesia P, et al. The quest for an optimized protocol for whole-heart decellularization: a comparison of three popular and a novel decellularization technique and their diverse effects on crucial extracellular matrix qualities. Tissue engineering. Part C Methods. 2011;17(9):915–926.
154. He M, Callanan A. Comparison of methods for whole-organ decel­lularization in tissue engineering of bioartificial organs. Tissue eng Part B Rev. 2013;19(3):194–208.
155. Guyette JP, Gilpin SE, Charest JM, Tapias LF, Ren X, Ott HC. Perfusion decellularization of whole organs. Nat Protoc. 2014;9:1451–1468.
156. Venkatasubramanian RT, Grassl ED, Barocas VH, Lafontaine D, Bis­chof JC. Effects of freezing and cryopreservation on the mechanical properties of arteries. Ann Biomed Eng. 2006;34(5):823–832.
157. Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials. 2006;27(19):3675–3683.
158. Zang M, Zhang Q, Chang EI, Mathur AB, Yu P. Decellularized tracheal matrix scaffold for tissue engineering. Plast Reconstr Surg. 2012;130(3):532–540.
159. Yang M, Chen CZ, Wang XN, Zhu YB, Gu YJ. Favorable effects of the detergent and enzyme extraction method for preparing decellular­ized bovine pericardium scaffold for tissue engineered heart valves. J Biomed Mater Res B Appl Biomater. 2009;91(1):354–361.
160. Cissell DD, Hu JC, Griffiths LG, Athanasiou KA. Antigen removal for the production of biomechanically functional, xenogeneic tissue grafts. J Biomech. 2014;47(9):1987–1996.
161. Wong ML, Wong JL, Athanasiou KA, Griffiths LG. Stepwise solubi­lization-based antigen removal for xenogeneic scaffold generation in tissue engineering. Acta Biomater. 2013;9(5):6492–6501.
162. Seif-Naraghi SB, Singelyn JM, Salvatore MA, et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013;5(173):173ra125.
163. Weymann A, Loganathan S, Takahashi H, et al. Development and evalua­tion of a perfusion decellularization porcine heart model – generation of 3-dimensional myocardial neoscaffolds. Circ J. 2011;75(4):852–860.
164. Badylak SF. Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transpl Immunol. 2004;12(3–4):367–377.
165. Manji RA, Zhu LF, Nijjar NK, et al. Glutaraldehyde-fixed biopros­thetic heart valve conduits calcify and fail from xenograft rejection. Circulation. 2006;114(4):318–327.
166. Sánchez Fernández PL, Fernández Santos ME, Costanza S, et al. Decelularización de corazones humanos para el desarrollo de matrices cardiacas que sirvan como soporte a la bioingeniería de tejidos cardiacos funcionales [Decellularization of human hearts for the development of heart matrices serve as a support for functional cardiac tissue bioengi­neering]. Abstract 31. Rev Esp Cardiol. 2011;64:Suppl 3:4. Spanish.
167. Seif-Naraghi SB, Salvatore MA, Schup-Magoffin PJ, Hu DP, Christman KL. Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A. 2010;16(6):2017–2027.
168. Paul A, Binsalamah ZM, Khan AA, et al. A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials. 2011;32(32):8304–8318.
169. Paul A, Elias CB, Shum-Tim D, Prakash S. Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization. Sci Rep. 2013;3:2366.
170. Paul A, Hasan A, Kindi HA, et al. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano. 2014;8(8):8050–8062.
171. Paul A, Hasan A, Rodes L, Sangaralingam M, Prakash S. Bioengineered baculoviruses as new class of therapeutics using micro and nanotech­nologies: principles, prospects and challenges. Adv Drug Deliv Rev. 2014;71:115–130.
172. Paul A, Shao W, Abbasi S, Shum-Tim D, Prakash S. PAMAM dendrimer-baculovirus nanocomplex for microencapsulated adipose stem cell-gene therapy: in vitro and in vivo functional assessment. Mol Pharm. 2012;9(9):2479–2488.
173. Vunjak-Novakovic G, Tandon N, Godier A, et al. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev. 2010;16(2):169–187.
174. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg. 2003;23(6):1002–1006; discussion 1006.
175. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Med. 2005;79(3):1072–1080.
176. Sutherland FW, Perry TE, Yu Y, et al. From stem cells to viable autolo­gous semilunar heart valve. Circulation. 2005;111(21):2783–2791.
177. Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg. 2000;119(2): 324–330.
178. Liang R, Woo SL, Takakura Y, Moon DK, Jia F, Abramowitch SD. Long-term effects of porcine small intestine submucosa on the healing of medial collateral ligament: a functional tissue engineering study. J Orthop Res. 2006;24(4):811–819.
179. Shimizu T, Yamato M, Isoi Y, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res. 2002;90(3):e40.
180. Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J Biomed Mater Res. 1993;27(10): 1243–1251.
181. Kushida A, Yamato M, Konno C, Kikuchi A, Sakurai Y, Okano T. Decrease in culture temperature releases monolayer endothelial cell sheets together with deposited fibronectin matrix from temperature-responsive culture surfaces. J Biomed Mater Res. 1999;45(4): 355–362.
182. Shimizu T, Sekine H, Yang J, et al. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. FASEB J. 2006;20(6):708–710.
183. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006;12(4):459–465.
184. Miyagawa S, Sawa Y, Sakakida S, et al. Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. Transplantation. 2005;80(11):1586–1595.
185. Masuda S, Shimizu T, Yamato M, Okano T. Cell sheet engineering for heart tissue repair. Adv Drug Deliv Rev. 2008;60(2):277–285.
186. Sekine H, Shimizu T, Sakaguchi K, et al. In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. Nat Commun. 2013;4:1399.
187. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861–872.
188. Didié M, Christalla P, Rubart M, et al.Parthenogenetic stem cells for tis­sue-engineered heart repair.J Clin Investig. 2013;123(3):1285–1298.
189. Zhang J, Klos M, Wilson GF, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res. 2012;111(9):1125–1136.
190. Gantz JA, Palpant NJ, Welikson RE, Hauschka SD, Murry CE, Laflamme MA. Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells. PloS One. 2012;7(10):e46971.
191. Kita-Matsuo H, Barcova M, Prigozhina N, et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PloS One. 2009; 4(4):e5046.
192. Kehat I, Khimovich L, Caspi O, et al. Electromechanical integra­tion of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004;22(10):1282–1289.
193. Zhang D, Shadrin IY, Lam J, Xian H-Q, Snodgrass HR, Bursac N. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials. 2013;34(23): 5813–5820.
194. Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B. Bio­wire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013;10(8):781–787.
195. Tulloch NL, Muskheli V, Razumova MV, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 2011;109(1):47–59.
196. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996;98(1):216–224.
197. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2013;126(11 Suppl 1):S29–S37.
198. Miki K, Uenaka H, Saito A, et al. Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. Stem Cells Transl Med. 2012;1(5):430–437.
199. Stevens KR, Kreutziger KL, Dupras SK, et al. Physiological func­tion and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A. 2009;106(39):16568–16573.
200. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myo­cardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367(9505):113–121.
201. Huikuri HV, Kervinen K, NiemeläM, et al; FINCELL Investigators. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J. 2008;29(22):2723–2732.
202. Hirsch A, Nijveldt R, van der Vleuten PA, et al; HEBE Investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coro­nary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32(14):1736–1747.
203. Traverse JH, Henry TD, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012; 308(22):2380–2389.
204. Perin EC, Willerson JT, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717–1726.
205. Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011;6(7):805–812.
206. Dib N, Dinsmore J, Lababidi Z, et al. One-year follow-up of feasi­bility and safety of the first US, randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv. 2009;2(1):9–16.
207. Ang KL, Chin D, Leyva F, et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med. 2008;5(10):663–670.
208. Losordo DW, Henry TD, Davidson C, et al; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428–436.
209. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329–2338.
210. Castaldo C, Di Meglio F, Miraglia R, et al. Cardiac fibroblast-derived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart. Biomed Res Int. 2013;2013:352370.
211. Chamberland C, Martinez-Fernandez A, Beraldi R, Nelson TJ. Embryonic decellularized cardiac scaffold supports embryonic stem cell differentiation to produce beating cardiac tissue. ISRN Stem Cells. 2014;2014:(2014).